APA (7th ed.) Citation

Fujita, K., Matsushita, Y., Toyoda, S., Kojima, T., Yamashita, S., Taniguchi, H., . . . Nishiyama, N. (2024). The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy. World Journal of Urology, 42(1), 1. https://doi.org/10.1007/s00345-024-05252-2

Chicago Style (17th ed.) Citation

Fujita, Kazutoshi, et al. "The Efficacy of Second-line Tyrosine Kinase Inhibitor for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Following First-line Immune-oncology Combination Therapy." World Journal of Urology 42, no. 1 (2024): 1. https://doi.org/10.1007/s00345-024-05252-2.

MLA (9th ed.) Citation

Fujita, Kazutoshi, et al. "The Efficacy of Second-line Tyrosine Kinase Inhibitor for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Following First-line Immune-oncology Combination Therapy." World Journal of Urology, vol. 42, no. 1, 2024, p. 1, https://doi.org/10.1007/s00345-024-05252-2.